Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

NCT05907291 is registered in ClinicalTrials.gov with Crinetics Pharmaceuticals Inc. as lead sponsor.

NCT NCT05907291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05907291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants With Congenital Adrenal Hyperplasia (TouCAHn)
Lead sponsor
Crinetics Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 3, 2023
Completion date
August 22, 2025
Enrollment
38 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

classic congenital adrenal hyperplasia, congenital adrenal hyperplasia